Compare Stocks: RXST, QDEL, CERS, and EMBC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.34 +2.6%	$2.58	$1.38 ▼ $3.47	$459.48M	1.83	1.72 million shs	1.84 million shs
EMBC Embecta	$5.88 +4.1%	$5.04	$2.77 ▼ $14.91	$320.13M	0.84	1.06 million shs	1.04 million shs
QDEL QuidelOrtho	$12.14 +12.7%	$13.46	$9.92 ▼ $35.58	$738.56M	0.79	1.52 million shs	2.69 million shs
RXST RxSight	$4.76 +1.7%	$6.00	$4.48 ▼ $13.22	$194.66M	1.15	766,877 shs	483,757 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	+2.63%	-4.49%	-9.65%	-27.33%	+49.04%
EMBC Embecta	+4.07%	-0.84%	+1.38%	+74.48%	-58.94%
QDEL QuidelOrtho	+12.72%	+12.10%	-13.10%	-28.59%	-59.51%
RXST RxSight	+1.71%	+1.93%	-25.39%	-15.30%	-45.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.34 +2.6%	$2.58	$1.38 ▼ $3.47	$459.48M	1.83	1.72 million shs	1.84 million shs
EMBC Embecta	$5.88 +4.1%	$5.04	$2.77 ▼ $14.91	$320.13M	0.84	1.06 million shs	1.04 million shs
QDEL QuidelOrtho	$12.14 +12.7%	$13.46	$9.92 ▼ $35.58	$738.56M	0.79	1.52 million shs	2.69 million shs
RXST RxSight	$4.76 +1.7%	$6.00	$4.48 ▼ $13.22	$194.66M	1.15	766,877 shs	483,757 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	+2.63%	-4.49%	-9.65%	-27.33%	+49.04%
EMBC Embecta	+4.07%	-0.84%	+1.38%	+74.48%	-58.94%
QDEL QuidelOrtho	+12.72%	+12.10%	-13.10%	-28.59%	-59.51%
RXST RxSight	+1.71%	+1.93%	-25.39%	-15.30%	-45.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERS Cerus	2.40	Hold	$5.25	124.36% Upside
EMBC Embecta	1.60	Reduce	$11.00	87.07% Upside
QDEL QuidelOrtho	1.50	Reduce	$13.63	12.23% Upside
RXST RxSight	1.92	Reduce	$8.17	71.69% Upside

Current Analyst Ratings Breakdown

Latest RXST, QDEL, CERS, and EMBC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$6.50 ➝ $5.75
9/22/2026	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$6.50 ➝ $5.50
9/14/2026	CERS Cerus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	RXST RxSight	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/20/2026	CERS Cerus	Freedom Broker Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.50
8/12/2026	QDEL QuidelOrtho	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/10/2026	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$8.00 ➝ $7.00
8/6/2026	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$5.50 ➝ $6.30
8/3/2026	EMBC Embecta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/28/2026	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$9.00 ➝ $5.50
7/28/2026	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Hold	$9.00 ➝ $5.50

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERS Cerus	$206.13M	2.29	N/A	N/A	$0.34 per share	6.88
EMBC Embecta	$1.08B	0.31	$4.17 per share	1.41	($11.12) per share	-0.53
QDEL QuidelOrtho	$2.73B	0.30	$21.30 per share	0.57	$28.27 per share	0.43
RXST RxSight	$134.48M	1.47	N/A	N/A	$6.70 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERS Cerus	-$15.63M	-$0.03	N/A	N/A	N/A	-3.06%	-10.19%	-3.14%	11/5/2026 (Estimated)
EMBC Embecta	$95.40M	$1.48	3.97	3.34	N/A	8.59%	-19.25%	10.82%	11/24/2026 (Estimated)
QDEL QuidelOrtho	-$1.13B	-$15.41	N/A	8.26	N/A	-39.20%	4.88%	1.63%	11/4/2026 (Estimated)
RXST RxSight	-$38.94M	-$1.13	N/A	N/A	N/A	-36.80%	-17.35%	-14.70%	11/4/2026 (Estimated)

Latest RXST, QDEL, CERS, and EMBC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q3 2026	EMBC Embecta	$0.2658	$0.56	+$0.2942	$0.36	$254.53 million	$271.70 million
8/6/2026	Q2 2026	QDEL QuidelOrtho	-$0.0488	$0.13	+$0.1788	-$1.36	$618.72 million	$630.90 million
8/5/2026	Q2 2026	RXST RxSight	-$0.3294	-$0.29	+$0.0394	-$0.29	$32.55 million	$33.74 million
7/30/2026	Q2 2026	CERS Cerus	-$0.0133	-$0.01	+$0.0033	-$0.01	$62.90 million	$63.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERS Cerus	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.04	0.68%	N/A	2.70%	N/A
QDEL QuidelOrtho	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Latest RXST, QDEL, CERS, and EMBC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/4/2026	EMBC Embecta	quarterly	$0.01	0.8%	8/27/2026	8/27/2026	9/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERS Cerus	0.49	1.83	1.07
EMBC Embecta	N/A	1.68	1.17
QDEL QuidelOrtho	1.43	1.39	0.76
RXST RxSight	N/A	4.07	3.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERS Cerus	78.37%
EMBC Embecta	93.83%
QDEL QuidelOrtho	99.00%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
CERS Cerus	5.30%
EMBC Embecta	1.30%
QDEL QuidelOrtho	1.10%
RXST RxSight	10.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERS Cerus	345	201.52 million	190.84 million	Optionable
EMBC Embecta	1,850	56.66 million	55.92 million	Optionable
QDEL QuidelOrtho	6,500	68.57 million	67.82 million	Optionable
RXST RxSight	461	41.59 million	37.41 million	Optionable

RXST, QDEL, CERS, and EMBC Headlines

Recent News About These Companies

Comparing RxSight (NASDAQ:RXST) & GN Store Nord (OTCMKTS:GNNDY)

October 5 at 5:28 AM | americanbankingnews.com

RxSight, Inc. (NASDAQ:RXST) Stock Now Rated "Reduce" by Sell-Side Analysts

October 3 at 2:15 AM | americanbankingnews.com

RxSight, Inc. (NASDAQ:RXST) Stock Has Consensus Target Price of $8.17 According to Analysts

October 3 at 2:13 AM | marketbeat.com

RxSight (NASDAQ:RXST) Cut to "Sell" at Wall Street Zen

October 3 at 1:17 AM | marketbeat.com

Bank of America Corp DE Buys New Shares in RxSight, Inc. $RXST

October 1, 2026 | marketbeat.com

RxSight stock faces a lower Jefferies target at USD 5.75

September 30, 2026 | ad-hoc-news.deA

Financial Analysis: Cerus (NASDAQ:CERS) vs. RxSight (NASDAQ:RXST)

September 25, 2026 | americanbankingnews.com

RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says

September 23, 2026 | finance.yahoo.com

RxSight stock falls as price targets are cut

September 22, 2026 | ad-hoc-news.deA

Jefferies Financial Group Issues Pessimistic Forecast for RxSight (NASDAQ:RXST) Stock Price

September 22, 2026 | marketbeat.com

Bank of America Has Lowered Expectations for RxSight (NASDAQ:RXST) Stock Price

September 22, 2026 | marketbeat.com

RxSight (NASDAQ:RXST) Rating Increased to Hold at Wall Street Zen

September 20, 2026 | marketbeat.com

RxSight (NASDAQ:RXST) Rating Lowered to Sell at Wall Street Zen

September 12, 2026 | marketbeat.com

RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of "Reduce" by Brokerages

September 8, 2026 | marketbeat.com

Ilya Goldshleger Sells 2,041 Shares of RxSight (NASDAQ:RXST) Stock

September 3, 2026 | insidertrades.com

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

August 26, 2026 | globenewswire.com

RxSight Inc.

August 18, 2026 | marketwatch.com

RxSight (RXST) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

RxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors

August 12, 2026 | tipranks.com

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2026 | zacks.com

RxSight (RXST) Stock Falls on Q2 2026 Earnings

August 5, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RXST, QDEL, CERS, and EMBC Company Descriptions

Cerus NASDAQ:CERS

$2.34 +0.06 (+2.63%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$2.35 +0.01 (+0.21%)

As of 10/5/2026 07:32 PM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Embecta NASDAQ:EMBC

$5.88 +0.23 (+4.07%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$5.40 -0.48 (-8.15%)

As of 10/5/2026 07:30 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

QuidelOrtho NASDAQ:QDEL

$12.14 +1.37 (+12.72%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$12.14 0.00 (0.00%)

As of 10/5/2026 07:30 PM Eastern

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

RxSight NASDAQ:RXST

$4.76 +0.08 (+1.71%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$4.76 0.00 (0.00%)

As of 10/5/2026 07:30 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXST, QDEL, CERS, and EMBC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXST, QDEL, CERS, and EMBC Earnings

Compare Dividends

Latest RXST, QDEL, CERS, and EMBC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXST, QDEL, CERS, and EMBC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RXST, QDEL, CERS, and EMBC Company Descriptions

Cerus NASDAQ:CERS

Embecta NASDAQ:EMBC

QuidelOrtho NASDAQ:QDEL

RxSight NASDAQ:RXST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools